Valuation: Acura Pharmaceuticals, Inc.

Market Cap 3.28M 2.87M 2.64M 2.45M 4.65M 311M 4.73M 31.71M 12.33M 154M 12.31M 12.04M 531M P/E 2020
-5.25x
P/E 2021 -25x
Enterprise Value 3.41M 2.99M 2.75M 2.55M 4.84M 324M 4.92M 33.01M 12.84M 160M 12.82M 12.54M 553M EV / Sales 2020
2.91x
EV / Sales 2021 20.9x
Free-Float
98.31%
Yield 2020 *
-
Yield 2021 -
Manager TitleAgeSince
Chief Executive Officer 67 2011-03-31
Director of Finance/CFO 62 2024-07-31
Chief Tech/Sci/R&D Officer 69 2009-01-31
Director TitleAgeSince
Chairman 75 1996-09-30
Director/Board Member 55 2002-11-30
Director/Board Member 83 1998-02-28
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%+1.39%+73.37%+128.84% 57.72B
-3.80%-6.24%+67.04%+86.36% 52.65B
+1.17%+5.83%+16.39%+468.18% 24.46B
+0.38%+1.33%-14.32%-11.76% 23.84B
-3.32%+2.66%+41.80%-6.03% 19.28B
-0.41%+4.85%+43.88%-26.80% 17.8B
+3.46%+17.72%+206.66%+364.07% 17.29B
-7.28%+9.26%+35.24% - 15.28B
+2.79%+4.91%+29.26%+195.60% 14.35B
Average -0.89%+5.15%+55.48%+149.81% 26.96B
Weighted average by Cap. -1.24%+2.58%+57.45%+139.23%

Financials

2020 2021
Net sales 3.57M 3.12M 2.88M 2.67M 5.07M 339M 5.15M 34.52M 13.43M 167M 13.4M 13.11M 578M 1.56M 1.37M 1.26M 1.17M 2.22M 148M 2.25M 15.12M 5.88M 73.21M 5.87M 5.74M 253M
Net income -1.21M -1.06M -974K -903K -1.71M -115M -1.74M -11.68M -4.54M -56.58M -4.54M -4.44M -196M -879K -769K -709K -657K -1.25M -83.42M -1.27M -8.5M -3.31M -41.17M -3.3M -3.23M -142M
Net Debt 5.86M 5.12M 4.72M 4.38M 8.31M 556M 8.44M 56.63M 22.02M 274M 21.99M 21.51M 948M 135K 118K 109K 101K 192K 12.81M 195K 1.31M 508K 6.32M 507K 496K 21.86M
Logo Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Employees
-